Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Tuberculosis (TB)


Facebook
        Twitter
        LinkedIn
        Syndicate





TB NOTES										Related Pages
										**TB Notes 4****2017**
Notes from the Director
Dear Colleague:
The past couple of months have been full of exciting updates from DTBE staff. Patient enrollment has begun for the “eDOT Study.” This study will assess whether directly observed therapy (DOT) that employs electronic communication methods, such as video via computer or cellphone, is a non-inferior approach to monitor TB treatment adherence, compared to traditional DOT. The study is a collaboration between the New York City Department of Health and Mental Hygiene, Columbia University, and DTBE. CDC’s Antibiotic Resistance Solutions Initiative funds the project.
On July 20th, DTBE presented the results of a systematic literature review and meta-analysis on the regimen of isoniazid and rifapentine (often referred to as “3HP”) to subject matter experts representing various fields, settings, and geographic locations in the United States. The meeting was intended to increase the transparency of DTBE’s guidance development, and to strengthen the quality of recommendations.
Another exciting advancement is CDC’s Epidemiology and Laboratory Capacity for Infectious Diseases Cooperative Agreement, which will fund a new national laboratory equipped to perform whole genome sequencing for all isolates of Mycobacterium tuberculosis received from newly diagnosed patients in the United States. The National Tuberculosis Molecular Surveillance Center will advance CDC, state, and local TB control programs’ abilities to identify and investigate outbreaks of TB, and strengthen surveillance of drug-resistant TB. This technology will help to target public health interventions and better respond to emerging resistance.
In other news, DTBE is exploring new ways to communicate relevant and timely information about TB prevention and control. The Division recently launched a new video for general audiences, “5 Things to Know about TB.”
Congratulations to the Tuberculosis Trials Consortium Drug Management Module Team, winner of the August 2017 National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Director’s Recognition Award! The team studies drug logistics and data collection for Study 31, a Phase III treatment-shortening trial for drug-susceptible TB being conducted at 22 domestic and international clinical trial sites, which are managed through an online system known as TBTC2.
Finally, I want to thank all of you for your hard work, resilience, and commitment to the important mission of TB elimination.
Philip LoBue, MD, FACP, FCCP
Director,
Division of Tuberculosis Elimination
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB PreventionOpen All Close All
Communications, Education, and Behavioral Studies Branch Updates**CDC Retires Latent TB Infection Mobile App**
The Latent Tuberculosis Infection Mobile app will be retired September 8, 2017.  Visit the Latent TB Infection Online Hub for clinical information, guidance, fact sheets, and messages on targeted testing recommendations for latent TB infection.  Updates about future mobile app developments will be posted here as well.
Submitted by John Parmer, PhD, MS, DTBE
**New Video: 5 Things to Know About TB**
DTBE is excited to debut a new video, “5 Things to Know About TB.”
5 Things to know about TB
The video highlights the continuing problem of TB in the United States and the importance of addressing latent TB infection through targeted testing and treatment.  The video was created for a general audience and can be shared on websites and social media platforms.  Since August 1, the video has been viewed over 4,000 times on YouTube, Twitter, and Facebook!
Submitted by Leeanna Allen, MPH, DTBE
**Tuberculosis: A New Screening Recommendation and an Expanded Approach to Elimination in the United States**
DTBE is working with partners and health care providers to promote testing and treatment for latent TB infection in at-risk communities.  As part of our provider outreach efforts, a new article “Tuberculosis: A New Screening Recommendation and an Expanded Approach to Elimination in the United States” has been published in the latest issue of the American Journal of Nursing (AJN).  This article provides nurses in a variety of clinical and community settings with
•	a general overview of TB transmission, pathogenesis, and epidemiology;
•	preventive care recommendations for targeted testing among high-risk groups; and
•	CDC and the U.S. Preventive Service Task Force’s recommendations on screening for latent TB infection.
Continuing education credit for the article is available.  We also invite you to listen to the “Behind the Article” podcast, as John Parmer, DTBE Health Communication Specialist, speaks with AJN editor-in-chief Shawn Kennedy about the important role nurses play in TB control programs, and the opportunities for nurses to expand TB testing and treatment in a variety of clinical and community settings.
Submitted by John Parmer, PhD, MS, DTBE
Laboratory Branch UpdatesDTBE is pleased to announce the establishment of the National Tuberculosis Molecular Surveillance Center (NTMSC) at the Michigan Department of Health and Human Services (MDHHS) Bureau of Laboratories. The center will be equipped to perform both conventional genotyping and whole genome sequencing (WGS) for all isolates of Mycobacterium tuberculosis. The NTMSC is supported by funding available through CDC’s Epidemiology and Laboratory Capacity for Infectious Diseases Cooperative Agreement (ELC) and is a new activity for CDC’s Antibiotic Resistance Laboratory Networkaimed at strengthening national TB surveillance for outbreak detection and drug resistance. MDHHS has extensive experience with the genotyping of M. tuberculosis and has participated in CDC-sponsored genotyping activities since the early 1990s. Their genotyping team currently performs MIRU-VNTR genotyping on 9,000 isolates and WGS on 750 isolates each year.
We anticipate that WGS typing will begin by March 2018. All isolates submitted for genotyping will be sequenced; no additional request for testing is necessary. As presented at this year’s National TB Controllers Association meeting, we have a multi-year plan for the incorporation of WGS results into the molecular surveillance of tuberculosis. In the years 2018 – 2020, conventional genotyping and WGS will be performed in parallel to allow for a 3-year transition between methods. Additional details and educational opportunities will be provided to partners over the next several months.
The NTMSC will also allow for national surveillance of molecular drug resistance and aid the potential establishment of new testing algorithms that could be used to develop new diagnostics or programs to aid clinical decision making. Alerts will be integrated into data analysis tools such that CDC is notified when resistance to rifampin, the most important first-line anti-tuberculosis drug, is detected. CDC will notify state partners to ensure isolates from patients with potentially drug-resistant TB are referred to a CLIA-compliant laboratory for additional testing.
Please note that the NTMSC is a surveillance activity for transmission and drug resistance and will not be replacing the clinical testing provided by DTBE’s Molecular Detection of Drug Resistance (MDDR) service or the National DST Reference Center located at the California Microbial Disease Laboratory. We look forward to the roll out of universal WGS in support of our public health partners.
Submitted by James Posey, PhD, DTBEClinical Research Branch UpdatesTB Trials Consortium (TBTC) Study 31 (also known as ACTG A5349; “Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: A randomized, open-label, controlled phase 3 clinical trial”) continues to enroll. As of July 24, 2017, the study had enrolled 1,085 participants.  The AIDS Clinical Trials Group (ACTG) network is collaborating with TBTC, contributing substantially to enrollment with 15 sites open for enrollment. The TBTC Study 32 (Opti-Q) has completed enrollment and is beginning data analysis. TBTC’s 40th semiannual meeting will be October 16-18, 2017, in Atlanta.  Those interested to attend should contact Ms. Barbara DeCausey (404-639-5330; tbtcresearchadmin@cdc.gov).
DTBE issued “Recommendations for Use of an Isoniazid-Rifapentine Regimen with Direct Observation to Treat (DOT) Latent Mycobacterium tuberculosis Infection” in 2011. Since then, new research on the 3HP regimen has been conducted and published, providing evidence that was not available in 2011. DTBE held a subject matter expert meeting in Atlanta, Georgia, on July 20, 2017, to present the results of a systematic literature review and meta-analysis on the 3HP regimen. Experts’ individual viewpoints about the strength of the presented evidence were obtained at the meeting. Information obtained from subject matter experts, representing various fields, settings, and geographic locations in the United States, will complement the systematic review process, and will be utilized to prepare updated guidance for use of 3HP for treatment of latent TB infection in the United States
Submitted by Barbara DeCausey, MPH, MBA, DTBESurveillance Epidemiology and Outbreak Investigations Branch UpdatesDTBE is focused on latent tuberculosis infection as a key to TB elimination. The Tuberculosis Epidemiologic Studies Consortium (TBESC) has developed and is testing a new latent TB infection surveillance system.
TBESC, in collaboration with Northrop Grumman (NG), developed the Surveillance for TB Elimination Management System (STEMS). STEMS is a real-time case management and surveillance system for latent TB infection currently used by all TBESC health department sites and the Dr. Bates Outreach Clinic, Arkansas Department of Health.
STEMS was beta tested at three sites–Hawaii, Arizona, and Washington. The system was improved using feedback from beta testing and pilot tested at all TBESC sites in September 2016. Updated versions are released periodically with improvements suggested by sites.
In addition to helping local health departments conduct latent TB infection surveillance and manage cases, data collected in STEMS will be used to create TB prevention cascades to cure for high-risk populations. Key variables identified throughout STEMS as minimum data elements, will help sites identify gaps in latent TB infection diagnosis, care, and treatment completion. Individual forms include registration, referral, patient history and risk factors, clinical evaluation, TST, QFT, T-SPOT, latent TB infection treatment, and discharge. A contact investigation module is currently under development.
Sites can either enter data directly into STEMS or coordinate with NG to upload data from existing electronic health record systems.  On June 6, 2017, Denver became the first site to electronically upload its data, followed by Nashville (July 6) and Maricopa (July 17).   These sites can now see their data in STEMS and make edits to their forms when needed. Miami is currently in preparation for electronic data transfer. The system offers efficient monitoring of patients with provision for calendar appointments, reminder alerts, and report generation. External sites including those in the Pacific Islands have expressed interest in using STEMS for latent TB infection case management and surveillance. Local areas interested in using STEMS should discuss the opportunity with their state health department and CDC public health advisor before contacting Kumar Batra for access to STEMS.
Submitted by Kiana N. Woods, MBA, M.Ed., DTBEField Services Branch Updates**The “eDOT  Study”**
On  June 23rd the New York City Department of Health and Mental  Hygiene’s Bureau of Tuberculosis Control (NYC DOHMH BTBC) held an in-service  for program staff to initiate a study to evaluate traditional directly observed  therapy (DOT) and electronic forms of DOT (eDOT) for TB treatment. The short  title is the “eDOT Study.” Funded through the CDC’s Antibiotic Resistance Solutions Initiative, the study  will assess whether eDOT that  employs electronic communication methods, such as video via computer or  cellphone, is a non-inferior approach to monitor TB treatment adherence,  compared to traditional in-person DOT (ipDOT), in which a trained person is in  the physical presence of patients as anti-TB drugs are ingested.
The  staff from four DOHMH operated TB clinics; Corona TB Chest Center in Queens,  Washington Heights TB Chest Center in Manhattan, Fort Greene TB Chest Center in  Brooklyn, and Morrisania TB Chest Center in the Bronx, gathered at program  headquarters. They listened as Director of Planning and Policy Dr. Michelle  Macaraig provided background on the study; Assistant Commissioner Dr. Joseph  Burzynski explained the study’s design; and Clinical Operations Director Mr.  Errol Robinson and Public Health Associate Mr. C. Kin Lam discussed logistics  and answered staff questions.
The assembled staff learned that after providing written informed consent, patients  newly diagnosed with drug-sensitive or non-rifamycin resistant TB would be randomly assigned to either ipDOT  or eDOT.  Following 20 doses of medicine,  participants who received ipDOT will switch to eDOT while those who were  initially assigned to eDOT will switch to ipDOT. Afterwards patients will  continue treatment using their preferred DOT method.
The team  aims to recruit 304 patients into this study over a two-year period.  The research team will compare:
The proportion of medication doses  that are directly observed by ipDOT versus eDOT,
Patient  adherence to scheduled DOT sessions,
Patient  characteristics associated with adherence across ipDOT, eDOT with live video,  and eDOT with recorded video,
The  type, frequency, and time between initial symptoms of medication side effects  and discussion with a medical provider across DOT methods,
Treatment outcomes, and
Patient perceptions of quality of care, overall satisfaction with  patient-staff rapport, and confidence to adhere across eDOT and ipDOT. Data for  an economic evaluation will be collected.The decision to discontinue eDOT and patient preferences for DOT methods  will be assessed as well.
field services branch
Corona, Washington  Heights, Morissania, and Fort Greene clinic staff have been working for several  months to train the study facilitators, Matthew Dias, Sarah Kiskadden-Bechtel,  and Michael Reeves on clinic operations and DOT procedures in preparation for  the official start of the study.
These staff warmly cheered for the study  facilitators as Dr. Burzynski introduced the facilitators to the entire  group that had gathered for the in-service.  Some good-natured competitive comments were heard as staff from the different clinics  claimed they would recruit the first patient into the study.
Planning for the eDOT Study began a little over a year ago as  a collaboration between the NYC DOHMH BTBC, Columbia University, and DTBE. Dr.  Burzynski serves as the DOHMH Principal Investigator for the “eDOT Study.” Dr.  Michelle Macraig is the co-Principal Investigator. Dr. Neil Schluger serves as  the Columbia University Study Lead. Drs. Joan Mangan and Neela Goswami serve as  the CDC Study Leads. The study team also includes: Dr. Sapna Bamrah Morris, Ms.  Christine Chuck, Dr. Richard Garfein (Consultant), Mr. C. Kin Lam, Dr. Diana  Nilsen, Dr. Margaret Oxtoby (Consultant), Mr. Errol Robinson, Dr. Brock  Stewart, Dr. Andrew Vernon (Consultant), Dr. Garrett Asay, and Mr. Marco  Salerno (Data Analyst). ****
The  group hopes to share preliminary results early next year.

Submitted  by: *C. Kin Lam, MPH  – Public Health Associate and Study Coordinator**Michelle  Macaraig, DrPH – NYC DOHMC BTBC Study Lead**Joan Mangan,  PhD, MST, DTBE – CDC Study Lead*New CDC Publications**July 2017** 
Barrett DH, Ortmann LW,  Brown N, DeCausey BR, Saenz C,  Dawson A. Public health research [Chapter 9]. In: Barrett DH, Ortmann LW,  Dawson A, Saenz C, Reis A, Bolan G,  eds. *Public Health Ethics: Cases Spanning the Globe*. Cham, Switzerland:  Springer; 2016.
Hall EW, Morris SB, Moore BK, Erasmus L,  Odendaal R, Menzies H, van der Walt M, Smith SE. Treatment  Outcomes of Children with HIV Infection and Drug-Resistant TB in Three  Provinces in South Africa, 2005-2008. Pediatr Infect  Dis J. 2017 Jul 19. doi: 10.1097/INF.0000000000001691. [Epub ahead of print]  PMID: 28746263.
Jones JM,  Armstrong LR. Delayed and  Unreported Drug-Susceptibility Testing Results in the US National Tuberculosis  Surveillance System, 1993-2014. Public Health Rep. 2017 Jan 1:33354917708989. doi:  10.1177/0033354917708989. [Epub ahead of print]. PMID: 28586626
Lempp JM, Zajdowicz  MJ, Hankinson AL, Toney SR, Keep LW, Mancuso JD, Mazurek GH. Assessment of the QuantiFERON-TB Gold In-Tube test for the detection of  Mycobacterium tuberculosis infection in United States Navy recruits. PLoS One. 2017 May  17;12(5):e0177752. doi: 10.1371/journal.pone.0177752. eCollection 2017. PMID:  28545136.
Parmer J, Allen L, Walton W. CE: Tuberculosis:  A New Screening Recommendation and an Expanded Approach to Elimination in the  United States. Am J Nurs. 2017 Jul 12. doi:  10.1097/01.NAJ.0000521946.45448.90. [Epub ahead of print]. PMID: 28704234.
Sandul AL, Nwana N,  Holcombe JM, Lobato MN, Marks S, Webb R, Wang SH, Stewart B, Griffin P, Hunt G,  Shah N, Marco A, Patil N, Mukasa L, Moro RN, Jereb J, Mase S, Chorba T,  Bamrah-Morris S, Ho CS. High Rate of Treatment Completion in Program Settings with 12-Dose Weekly  Isoniazid and Rifapentine (3HP) for Latent Mycobacterium tuberculosis  Infection. Clin  Infect Dis. 2017 May 30. doi: 10.1093/cid/cix505. [Epub ahead of print]. PMID:  28575208.  
Smith SE, Pratt R, Trieu L, Barry PM, Thai  DT, Ahuja SD, Shah S. Epidemiology of  pediatric multidrug-resistant tuberculosis in the United States, 1993-2014. Clin Infect Dis. 2017 Jun 19. doi:  10.1093/cid/cix561. [Epub ahead of print] PMID: 28633501.
Teeter LD, Kammerer SJ, Ghosh S,  Nguyen DTM, Vempaty P, Tapia J, Miramontes R, Cronin WA, Graviss EA, on behalf  of the Tuberculosis Epidemiologic Studies Consortium. Evaluation of 24-locus  MIRU-VNTR genotyping in Mycobacterium tuberculosis cluster investigations in  four jurisdictions in the United States, 2006 – 2010. Tuberculosis. 2017;  106:9-15. doi: http://dx.doi.org/10.1016/j.tube.2017.05.003.
**August 2017**
Badal-Faesen S, Firnhaber C, Kendall MA, Wu X, Grinsztejn B, Escada  RODS, Fernandez M, Hogg E, Sanne I, Johnson P, Alland D, Mazurek GH, Benator  DA, Luetkemeyer AF; AIDS Clinical Trials Group A5295; Tuberculosis Trials  Consortium Study 34 Teams. Impact of Larger  Sputum Volume on Xpert<sup>®</sup> MTB/RIF Assay Detection of  Mycobacterium tuberculosis in Smear-Negative Individuals with Suspected  Tuberculosis. J Clin Med. 2017 Aug 7; 6(8). pii: E78. doi:  10.3390/jcm6080078. PMID: 28783093
  Malekinejad M, Parriott A, Viitanen AP,  Horvath H, Marks SM, Kahn JG. Yield of  community-based tuberculosis targeted testing and treatment in foreign-born  populations in the United States: A systematic review. PLoS One. 2017 Aug 7; 12(8):e0180707. doi:  10.1371/journal.pone.0180707. eCollection 2017. PMID: 28786991.
  Savic RM, Weiner M, MacKenzie WR, Engle M,  Whitworth WC, Johnson JL, Nsubuga P, Nahid P, Nguyen NV, Peloquin CA, Dooley KE,  Dorman SE; Tuberculosis Trials Consortium of the Centers for Disease Control  and Prevention. Defining the optimal dose of rifapentine for  pulmonary tuberculosis: Exposure-response relations from two-phase II clinical  trials. Clin Pharmacol Ther. 2017  Aug;102(2):321-331. doi: 10.1002/cpt.634. Epub 2017 Mar 2. PMID: 28124478.
							
					
						Page last reviewed:  September 12, 2017					Content source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To Subscribe to the TB Notes Newsletter, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue